Inhaled drugs as risk factors for communityacquired pneumonia

European Respiratory Journal

Volumn 36, Issue 5, 2010, Pages 1080-1087

  Almirall, J ^a   Bolibar I ^a   Serra Prat, M ^b   Palomera, E ^b   Roig, J ^f   Hospital, I ^c   Carandelle, E ^d   Agusti M ^c   Ayuso, P ^e   Estela, A ^d   Torres, A ^c   De Salas, J M ^g   Costa, J ^g,h   Tristany, M ^g   Grau, M J ^g   Sancho, S ^g   Miguel, E ^g   Fradera, M ^g   Ochoa, I ^g   Castany, M J ^g   Quilez, A ^g   Marina, V ^h   Subias, P ^h   Jimeno, B ^h   Bradnovich, ^h   Rodriguez, M ^h   Ramon, E ^h   Gardella, A ^h   Gines C ^h   Montero, J C ^h   Flores, P ^h   Serra, P ^h   Torrellas, E ^h   Serrano, C ^h   Pubill, M ^h   Gost, J ^h   Buxade I ^h   Mussoll, J ^h   Mestres, X ^h   Armada, A ^h   Mallafre J ^h   Roger, M ^h   Gros, M T ^h   Les, N ^h   Joanola, J ^h   Domenech J ^h   Bundo M ^h   Trilla, M ^h   Massons, J ^h   Montero, J ^h   Zurilla, E ^h   Alegre, M ^h   Papiol, M ^h   Marti O ^h   Catala M ^h   Martinez, M A ^h   Casanovas, A ^h,l   Beisani, I ^h   Tria, C ^h   Diaz, E ^h   Toran P ^h   Aizpurua, M M ^h   Lozano, G ^h   Casals, J ^h   Sorribes, J ^h   Torrellas, D ^h   Casas, A ^h   Bernad, J ^h   De Montoliu, A ^h   Gaya, J ^h   Valles R ^h   Vazquez, A ^h,h,k   Peiro R ^h   Areste G ^h   Mengual, G N ^h   Vines M C ^h   Almerich, E ^h   Lopez, M A ^h   Bel, J ^h   Gosalves, A ^h   Macip, S ^h   Carrillo, E ^h   Paulo, P ^h   Pol, M ^h   Sala, J ^h,l   Mir, P ^h   Anglada, J L L ^h   Salabarnada, J ^h   Sanz, E ^h   Gorgas, F ^h   Ribas, A ^h   Fau, E ^h   Pellicer, I ^h   Morales, S ^h   Burdoy, E ⁱ   Bartolome M ⁱ   Corona, E ⁱ   Mateu, L ⁱ   Paret, M ⁱ   Verde, Y ⁱ   Borras A ^j   Aznar, F ^j   Riera, F ^k   Gil, P ^k,l   Colom, I ^h   Calvet, E ^h   Nicolas J ^h   Ruiz, J ^h   Carrera, P ^h   Legazpi, I ^h   Planellas, F ^h   Beltran, A ^h   Planas, T ^h   Rovira, J ^h   De Ciurana, M ^h   Xargay, C ^h   Cortes R B ^h   Paredes, J ^h   Olive, J G ^h   Montoya, P ^h   El Hosn Makarem, J A ^h   Pelaez, F ^h   Ubieto, A ^h   Burcet, F X ^h   Alcantarilla, D ^h   De Ribot, J ^h   Gorgot, M R ^h   Bas, R A ^h   Rosa, M B ^h   Castells, J ^h   Castillo, J A ^h   Benet, J M ^h   Caballero, J C ^h   Llach, J ^h   Sanglas, J ^h   Moral, V ^h   Navarro, M ^h   Torrent, J C ^h   Rodriguez D ^h   Rius, X ^h   Solanella, J ^h   Fallada, A ^l   Cardona, J I ^l   Ferrer, J ^l   Josa, A ^l   Solis M J ^l   Guerri F ^l   Boj, J ^l   Ramon, C ^l   Caballol, R ^l   Navarro, L ^l   Masque J ^l   Murillo, M J ^l   Llovet, M D ^l   Guinea, I ^l   Juarez M M ^l   Alvarez, M ^l   Blade J ^l   Sanchez Oro I ^l   Martin, F ^l   Cabre J J ^l   Frigola, J ^l   Requena, J ^l   Fava E ^l   Pinazo, M J ^l   Ros, M ^l   Borras S ^l   Nolla, C ^l   Bitria J ^l   Araujo, O ^l   Alonso, M ^l   Glaria, T ^l   Chacon, A ^l   Satue E ^l   Collado, A ^l   Llor, Ll ^l   Montanyes D ^l   Garcia, G ^l   Arasa, M J ^l   Yoldi, A ^l   Viloria, I ^l   Vallespi, F ^l   Clua, J L L ^l   Basart, J M ^l   Ciurana, E ^l   Monclus, J F ^l   Vinas L ^l   Checa, E ^l   Marin, J ^l   Santigosa, J ^l   Basora, T ^l   Gallego, F ^l   Martin, E ^l   Rosello M ^l   Arayo, I ^l   Palacios, F ^l   Donado, A ^l   Marimon, J ^l   Costa, B ^l   Gutierrez C ^l   Molto E ^l   Isach, A ^l   Izzeddin, N ^l   Campani, M ^l   Ferre J ^l   Fernandez A ^l   Jove J ^l   Vilalta, J ^l   Ribera, E ^l   Fernandez M ^l   Ochoa, O ^l   Vila, A ^l   Pujol, J ^m   Navarro, M A ^m   Campillos, C ^h   Juarez, A ^h   Perez, J ^h   Casado, I ^h   Paredes, E ^h   Rodriguez, J ^h   Sola Y ^h   Berdie J ^h   Andres M J ^h   Barragan, B ^h   Torras, A ^h   Madrid, M ^h   Gonzalez, S ^h   Fuentes, A ^h   Iniguez M ^h   Guasch, J ^h   Sanchez F ^h   Pascual, J ^h   Castello A ^h   Gomez Ll ^h   Mateu, C ^h   Arranz, J ^h   Fe A ⁿ   Puig, B ^o   Gutierrez M ^f,h   Morant, Ll ^h   Llull, M ^h   Estelrich, J ^h   Quintana, L ^h   Llabres C ^h   Sureda, M M ^h   Cuevas, L ^h   Munoz Y ^p   Llobera, J ^p   Marin, P ^q   Garcia, C ^q   Moreno, P ^q   Coll, M ^r   Palma, C ^r   Ribera, C ^r   Aldosa, J ^h   Alonso, C ^h   Berges A ^h   Burgues J ^h   Burgues Ll ^h   Busquets, J ^h   Casal, D ^h   Cerdan N ^h   Crespo, X ^h   Duat, R ^h   Escoda, J ^h   Fiter, M ^h   Font, A ^h   Fraysse, M ^h   Fuentes, S ^h   Garcia Nunez R ^h   Lopez Pinacho T ^h   Masardo, M ^h   Martinez Illescas J ^h   Morisset, P ^h   Pallares M ^h   Perez Serra R ^h   Pla A ^h   Pons, E ^h   Ruiz, A ^h   Rodriguez Picart J C ^h   Sanchez Claver J ^h   Sylvestre, E ^h   Tolosa, R ^h   Touceda, J A ^h   Varela, J R ^h   Vidal, J C ^h   Amate, M ^f   Bara, C ^f   Becerra, O ^f   Bellmunt, R ^f   Boneu, F ^f   Bozal, J ^f   Burillo, C ^f   Diaz A ^f   Gonzalez N ^f   Granyena, A ^f   Infante, C ^f   Leal, M ^f   Linares, M ^f   Magallon J ^f   Marques J ^f   Marti M J ^f   Miralles, J C ^f   Mora, C ^f   Palacin J M ^f   Pons, J ^f   Prats, G ^f   Pujal, G ^f   Sanjuan M ^f   Segarra, X ^f   Solis J ^f   Trelles, H ^f   De Celis, G ^f   Latorre, X ^f   Sarroca, O ^f   Briceno H ^f   more..

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE MATARÓ   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Servei Balear de la Salut (IB Salut)   (Spain)

^e INSALUD   (Spain)

^f HOSPITAL NOSTRA SENYORA DE MERITXELL   (Andorra)

^g INSTITUT CATALÀ DE LA SALUT   (Spain)

^h Health Basic Area of Canet de Mar and Sant Pol de Mar ^*  (Andorra)

ⁱ Health Basic Area of Mataró Centre Mataró Consorci Sanitari del Maresme   (Spain)

^j ABS Mataró Centre   (Spain)

^k GEMA SL   (Spain)

^l Health Basics Areas of ICS   (Spain)

^m ICS   (Spain)

ⁿ Health Basic Area of Escola Graduada (ICS)   (Spain)

^o Health Basic Area of Coll d'en Rabassa (ICS)   (Spain)

^p IB SALUT   (Spain)

^q Health Basics Areas of INSALUD   (Spain)

^r Àrea de Vigilància Epidemiològica del Ministeri de Salut   (Andorra)

more..

Author keywords

Community acquired pneumonia; Inhaled drug treatment; Risk factors

Indexed keywords

ACETYLCYSTEINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; STEROID; THEOPHYLLINE;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; ASTHMA; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; ASTHMA; BRONCHODILATOR AGENTS; CASE-CONTROL STUDIES; CHOLINERGIC ANTAGONISTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STEROIDS;

EID: 78349272090     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00022909     Document Type: Article

References (42)

1. Woodhead MA, Macfarlane JT, McCracken JS, et al. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1: 671-674.
2. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977-988.
3. Almirall J, Casado M, Valls F, et al. Estudio prospectivo de las neumonías extrahospitalarias atendidas en un hospital general. Error diagnóstico. [Prospective study of community-acquired pneumonia sen in a general hospital. Diagnostic errors.] Med Clin (Bar) 1991; 97: 250-254.
4. Ausina V, Coll P, Sambeat M, et al. Prospective study on the etiology of community-acquired pneumonia in children and adults in Spain. Eur J Clin Microbiol Infect Dis 1988; 7: 342-347.
5. Oseasohn R, Skipper BE, Tempest B. Pneumonia in aNavajo community: a two-year experience. Am Rev Respir Dis 1978; 117: 1003-1009.
6. Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000; 94: 422-427.
7. LaCroix AZ, Lipson S, Miles TP, et al. Prospective study of pneumonia hospitalizations and mortality of US older people: the role of chronic conditions, health behaviours, and nutritional status. Public Health Rep 1989; 104: 350-360.
8. Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352: 2082-2090.
9. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 2008; 31: 1274-1284.
10. White DA. Drug-induced pulmonary infection. Clin Chest Med 2004; 25: 179-187.
11. Mason CM, Nelson S. Pulmonary host defenses and factors predisposing to lung infection. Clin Chest Med 2005; 26: 11-17.
12. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
13. Dolovich MA, MacIntyre NR, Anderson PJ, et al. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. Respir Care 2000; 45: 589-596.
14. Woodhead M. Inhaled corticosteroids cause pneumonia... or do they? Am J Respir Crit Care Med 2007; 176: 111-112.
15. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease www.goldcopd.com/Guidelineitem. asp?l1=2&l2=1&intId=989 Date last updated: December 2007. Date last accessed: September 19, 2008.
16. Grupo Español del Estudio Europeo del Asma. Estudio Europeo del Asma. Prevalencia de síntomas relacionados con el asma in cinco áreas españolas. [The European Asthma Study. The prevalence of asthma-related symptoms in 5 spanish areas. The Spanish Group of the European Asthma Study.] Med Clin (Barc) 1995; 104: 487-492.
17. Inman WH, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969; 2: 279-285.
18. Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 2006; 144: 904-912.
19. Sing S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and metaanalysis. JAMA 2008; 300: 1439-1450.
20. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166.
21. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-149.
22. Nannini LJ, Cates CJ, Lasserson TJ, et al. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting betaagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 4: CD006829.
23. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
24. Salas M, Hofman A, Stricker BH. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149: 981-983.
25. Kobayashi N, Lisura M. Bacterial pneumonia in asthmatic patients. Arerugika 2002; 13: 329-335.
26. To M, To Y, Yamada H, et al. Influence of inhaled corticosteroids on community-acquired pneumonia in patients with bronchial asthma. Intern Med 2004; 43: 674-678.
27. Koivula I, Sten M, Mäkelä PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313-320.
28. Juhn YJ, Kita H, Yawn BP, et al. Increased risk of serious pneumococcal disease in patients with asthma. J Allergy Clin Immunol 2008; 122: 719-723.
29. Gross NJ. Tiotropium bromide. Chest 2004; 126: 1946-1953.
30. Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 297-304.
31. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD006101.
32. Koumis T, Samuel S. Tiotropium bromide: a new long-acting bronchodilator for the treatment of chronic obstructive pulmonary disease. Clin Ther 2005; 27: 377-392.
33. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555.
34. Salpeter SR, Buckley NS. Systematic review of clinical outcomes in chronic obstructive pulmonary disease: beta-agonist use compared with anticholinergics and inhaled corticosteroids. Clin Rev Allergy Immunol 2006; 31: 219-230.
35. Jara M, Lanes SF, Wentworth C 3rd, et al. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007; 30: 1151-1160.
36. Stoodley RG, Aaron SD, Dales RE. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: ametaanalysis of randomized clinical trials. Ann Emerg Med 1999; 34: 8-18.
37. Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339.
38. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380-390.
39. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
40. TashkinDP,Celli B, Senn S, et al. A4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
41. Hanania NA, Donohue JF. Pharmacologic interventions in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 526-534.
42. Profita M, Giorgi RD, Sala A, et al. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy 2005; 60: 1361-1369.